Profiel
Sara Blum Sherman is currently working as Vice President-Investor Relations at Exscientia AI Ltd.
and Exscientia Plc.
She previously worked as Senior Director-Investor Relations & Strategy at DBV Technologies SA from 2016 to 2020 and as Head-Investor Relations at UroGen Pharma Ltd.
Actieve functies van Sara Blum Sherman
| Bedrijven | Functie | Begin |
|---|---|---|
| EXSCIENTIA PLC | Investor Relations Contact | 01-08-2021 |
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Investor Relations Contact | - |
Eerdere bekende functies van Sara Blum Sherman
| Bedrijven | Functie | Einde |
|---|---|---|
| UROGEN PHARMA LTD. | Investor Relations Contact | 01-08-2021 |
| DBV TECHNOLOGIES | Public Communications Contact | 01-09-2020 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| DBV TECHNOLOGIES | Health Technology |
| UROGEN PHARMA LTD. | Health Technology |
| EXSCIENTIA PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
